A single dose of PAN treatment successfully increased TRPC5 single-channel activity in response to the TRPC5 agonist riluzole, while systemic co-administration of AC1903 with PAN in rats significantly reduced TRPC5 activity from isolated glomeruli (Figure 2A). The gene discussed is TRPC5; the disease is polyarteritis nodosa.